The kynurenine pathway of tryptophan metabolism accounts for most of the tryptophan that is not committed to protein synthesis and includes compounds active in the nervous and immune systems. Kynurenine acts on the aryl hydrocarbon receptor, affecting metabolism of xenobiotics and promoting carcinogenesis. Quinolinic acid is an agonist at N-methyl-D-aspartate receptors (NMDAR), but is also pro-oxidant, has immunomodulatory actions and promotes the formation of hyperphosphorylated tau proteins. Kynurenic acid blocks NMDARs and 7-homomeric nicotinic cholinoceptors but is also an agonist at the orphan G-protein-coupled receptor GPR35. 3-hydroxykynurenine and 3-hydroxyanthranilic acid have pronounced redox activity and regulate T cell function. Cinnabarinic acid can activate metabotropic glutamate receptors.
hippocampal slices could not be entirely explained by blockade of NMDARs [11, 12] (Figure 2 ). However, a new receptor target was later identified as homomeric 7-nicotinic cholinoceptors (7NR), where kynurenic acid was a non-competitive antagonist [13] . The effect was observed initially in neuronal cultures, where kynurenic acid appeared more active as an antagonist of 7NRs than NMDARs. However, this differential potency did not apply to neurones in more intact, multicellular preparations such as slices. A later examination of hippocampal interneurones confirmed that kynurenic acid could block 7NR on these cells excited by exogenously applied agonists or synaptically released acetylcholine, although with a potency that was not fundamentally different from that which blocked NMDAR [14] . Thus, the sensitivity of 7NR is probably dependent on experimental conditions and location, differing also between synaptic and extrasynaptic sites. Sensitivity may also change with age [15] . In addition, kynurenic acid produced endogenously within brain slices from kynurenine is better able to block NMDAR and 7NR than kynurenic acid which is added exogenously [15] , so that its physiological activity at this site may be underestimated.
AD. These data are especially relevant to the treatment of Alzheimer's disease. Agonists acting at 7NR are particularly good at facilitating learning and memory processes in animal models and in patients with AD [16, 17] .
Conversely, a loss of cholinergic projections from the septum to the hippocampus or from nucleus basalis to the neocortex results in substantial deficits in learning, as does the administration of cholinoceptor antagonists.
Although there are relatively few studies of the kynurenine pathway in patients with AD, IDO is activated in the disease leading to a high kynurenine:tryptophan ratio in blood [18, 19] . This would be expected to raise the endogenous levels of kynurenic acid which, by blocking glutamate and nicotinic receptors, could contribute to cognitive dysfunction.
However, the effects of compounds that inhibit KMO are not limited to increasing the levels of kynurenic acid. A recent study showed that KMO inhibition also produces a decrease in the levels of glutamate in a transgenic mouse model of Alzheimer's disease. This was associated with a reduction in the loss of synapses in the brain, with improved memory in a spatial learning task and reduced anxiety behaviour [20] . This would be consistent with the view that part of the neurodegeneration seen in Alzheimer's disease is caused by the excitotoxic effects of endogenous glutamate. Since KMO inhibition should also reduce the formation of quinolinic acid, it is possible that this NMDA agonist may also have contribute to the excitotoxicity in AD, but its role was not assessed directly in that study.
HD. There are many neurochemical similarities observed in the post mortem striatum of patients with HD and animal models produced by quinolinic acid injections [21, 22] , with additional aspects of motor function in common [23] .
Patients also exhibit reduced levels of kynurenic acid in the brain [24] , although 3HAA concentrations are raised, consistent with the increased concentrations of quinolinic acid found in the brains of animal models of HD [25, 26] . In the most commonly used R6/2 mouse model of the disorder, KMO activity is increased and inhibition of the enzyme prolongs the life span of the animals as well as protecting neurons and synapses and suppressing microglial activation [20] .
Recent clinical studies have obtained strong support for a role of kynurenines with the finding of highly significant correlations between the blood concentrations of kynurenine and the number of DNA codon repeats (CAG) in the abnormally extended nucleotide sequence of the huntingtin gene [27] .
Together there results are consistent with the view that the molecular aberration in HD is associated with altered kynurenine metabolism, which could account for at least some of the symptoms and progression of the disease.
Schizophrenia. In schizophrenia, the suppression of dopaminergic function by neuroleptic drugs can reduce the early, positive symptoms which are caused by overactivity of the ventral tegmental projections to the striatum and nucleus accumbens. Classical drugs have little effect on later, negative symptoms which are associated with underactivity of dopaminergic projections to prefrontal cortex [28] . Underlying these disturbances is a hypo-glutamatergic state [29] the induction of which, in animals, is widely used to model schizophrenic symptoms [30] . Thus, compounds that block NMDARs, such as phencyclidine, can induce many of the cardinal symptoms of schizophrenia such as a loss of pre-pulse inhibition [31] . A hypoglutamatergic state could be produced by raised levels of kynurenic acid, and several studies show up to five times the normal level of kynurenate in the cerebrospinal fluid (CSF) of schizophrenic patients [32, 33] . The administration of kynurenic acid (directly or via its precursor, kynurenine), produces a reduction of extracellular dopamine concentrations, as seen in the prefrontal cortex in schizophrenia. Conversely, reduced kynurenic acid concentrations promote dopamine release in striatum [34] and hippocampus [35] , which may account for the wide spectrum of cognitive dysfunction in schizophrenia. The mechanism of this effect is unclear at the cellular and network level, although it has been suggested that the interaction results from a blockade by kynurenic acid of glutamate or 7NR on dopaminergic nerve terminals or local astrocytes [36] . There is a diminished activation of 7NRs in schizophrenia, and the administration of agonists acting at 7NRs can reduce many of the positive and negative aspects of cognitive dysfunction in schizophrenia and animal models [37, 38] .
Slightly complicating this picture is a report that kynurenic acid may facilitate activity of AMPA receptors by modulating their desensitisation [39] and that it produces antagonism of AMPA when used at higher concentrations. To date, however, these results have not been confirmed and may represent, at best, a minor action of kynurenic acid.
Collectively these data suggest that the blockade of glutamate, NMDARs and 7NRs by kynurenic acid could account for many of the learning and cognitive problems in AD and schizophrenia. Indeed, deletion of the enzyme which synthesises kynurenic acid -kynurenine aminotransferase II (KATII) -has a pro-cognitive effect in animals [40] , supporting the view that even normal levels of kynurenate may have a limiting effect on cognitive function. In addition, the plasma concentration of kynurenic acid increases with age in humans and could contribute to age-related deficiencies in memory and cognition [41] .
Alternative molecular targets for kynurenic acid

GPR35
Another target of kynurenic acid may be the erstwhile orphan G-proteincoupled receptor GPR35, at which kynurenic acid is one of the most potent endogenous agonists yet identified [42] (Figure 2 ). The highest levels of GPR35 are in the intestine where, in patients with inflammatory bowel disease, kynurenic acid levels are significantly greater than in control subjects [43] . The receptor has been implicated in several aspects of gastrointestinal dysfunction including the development of gastric cancer [44] . Its role in the CNS is less clear although loss of GPR35 may underlie at least one form of mental retardation [45] . The agonist activity of kynurenic acid could therefore be important in the early development of the CNS. Indeed, recent data demonstrate that increasing kynurenic acid levels prenatally leads to marked changes in the expression of neurodevelopmental proteins in postnatal life [46] .
Expression of GPR35 in immune cells occurs in neutrophils, monocytes, T cells and dendritic cells, but less so in natural killer (NK) cells and eosinophils.
Amongst peripheral blood cells, GPR35 expression is greatest in circulating monocytes which, in the presence of kynurenic acid, bind firmly to endothelium, suggesting a role for this ligand-receptor combination in monocyte extravasation [47] . In monocytes, macrophages and glial cells, GPR35 interaction with kynurenic acid down-regulates the proinflammatory phenotype induced by bacterial lipoloysaccharides (LPS), notably reducing TNF- and high-mobility group box 1 protein (HMGB1) [48] (Figure 2 ). A proposed intracellular mechanism for this effect is the lowering of intracellular calcium, mediated by GPR35-linked adenylate cyclase inhibition and reduced intracellular cAMP; a similar explanation has been advanced to explain reduced calcium-dependent release of glutamate from GPR35-expressing glia treated with kynurenic acid [42] . There is currently little information available about other immune system cells that express GPR35, except for invariant natural killer cells (iNKT) which, on specific stimulation by glycolipids (presented by antigen presenting cells)
produce a large variety of cytokines and chemokines [49] ; GPR35 engagement by kynurenic acid downregulates IL-4 but not IFN- and probably has other actions yet to be identified.
Growth factors
Although the blockade of glutamate receptors by kynurenic acid may cause the cognitive dysfunction discussed above, the same blocking action can protect the brain against the excitotoxic effects of abnormally high glutamate receptor activation. This protective activity may be enhanced by effects on growth factors since kynurenic acid can increase the expression of nerve growth factor (NGF) in glial cells [50, 51] . NGF is of special importance because of its regulation of proliferation and subsequent maintenance of cholinergic neurones in the CNS, and hence of relevance to AD and schizophrenia [52] . In contrast, kynurenic acid reduced the release of fibroblast growth factor-1 (FGF-1) in several different experimental models [53] , so that its net effects on cell viability may depend on a balance of changes in different growth factors.
Although these results are exceptionally interesting for understanding the neuroprotective effects of kynurenic acid, therefore, work should be extended to other growth factors. For example, because kynurenic acid can enhance proliferation of some glial cells, it would be of value to examine the expression and release of gliotropic factors as well as brain-derived growth factor (BDNF).
A kynurenine receptor?
A most surprising discovery has been that kynurenine itself -a compound regarded as being almost devoid of biological activity -can act at the aryl hydrocarbon receptor (AHR) [54] (Figure 3) . The AHR is a cytosolic transcription factor which is the primary binding site for the potent cellular toxin 2,3,7,7-tetrachlorodibenzo-p-dioxin, (often known as 'dioxin'). The receptor is a component of the 'xenobiotic response element' which is important in the detection of foreign substances. The AHR acts on a range of major metabolising enzymes including phase I and phase II enzymes such as CYP1A1, CYP1A2 and CYP1B1 and gives animals the ability to detect and respond to a wider range of xenobiotics and toxins than would otherwise be possible. The AHR appeared early in evolution and exists in a variety of species.
Kynurenine may be the primary natural, endogenous ligand at the AHR, promoting protection of the organism, reducing illness triggered or caused by chemicals, and even prolonging survival [54, 55] . This view is supported by work in which the AHR has been deleted, leaving animals with physiological aberrations and slowed development [56, 57] .
The AHR may be associated with fundamental aspects of cell biology including the proliferation and differentiation of cells early in embryonic development, especially in the blood and lymphoid tissues as well as neurons.
This would explain a requirement for the AHR in tissue formation [58] . In Furthermore, co-cultures of AHR(-/-)DCs and naïve T cells suppressed differentiation of the latter into Treg cells, while addition of kynurenine to this system restored differentiation into anti-inflammatory T reg cells and reduced differentiation into the highly inflammatory Th17 cells [55] . Thus, kynurenine acts on DCs to produce a powerfully anti-inflammatory action (Figures 3, 4) .
Whether this effect of kynurenine is also mediated through the AHR remains unclear.
In the adaptive immune system, AHRs are also constitutively expressed on Certainly, the levels of 3-HAA can change dramatically. In a study of patients newly diagnosed with osteoporosis, plasma levels of 3-HAA were less than 10% of those in control subjects. Over two years' treatment with standard drugs, this level rose to control values in parallel with significant improvements in bone density [69] . Intriguingly, this leap in plasma 3-HAA concentrations was accompanied by the converse change in anthranilic acid, another kynurenine metabolite whose origin, metabolism and biology remain largely unexplored. A similar reversal in the ratio of 3-HAA and anthranilic acid has been discovered in patients with Huntington's disease (HD), stroke and chronic brain injury [70] .
Cinnabarinic acid is a metabolite of 3-HAA formed by its oxidative dimerisation. This compound is able to induce apoptosis of T cells with a potency about ten times that of 3-HAA itself [71] , and it may, therefore, be the compound responsible for some of the effects hitherto attributed to 3-HAA. In addition, cinnabarinic acid activates mgluR4 [72] , raising the possibility that it may have relevance to the development or treatment of several CNS disorders, especially Parkinson's disease [73] .
A wider role in the immune system
In addition to the effects that kynurenines have on immune function via the AHRs, there is increasing evidence for more generalised actions on the immune system. The inhibitory effect of IFN- on the growth and proliferation of Toxoplasma parasites cultured with fibroblasts results from its activation of the first enzyme in the kynurenine pathway -IDO [74] . The activation produced a suppression of cell proliferation which was restored by adding tryptophan, giving rise to the 'tryptophan depletion' hypothesis which posits that the activity of IDO reduces the local concentrations of tryptophan, which in turn limits protein synthesis to rapidly dividing cells.
That observation marks the start of interest in kynurenine effects in the immune system. A second landmark discovery was that inhibition of IDO, using 1-methyl-tryptophan, produced a loss of embryos in pregnant rats [75] . The proposed explanation was that the placenta normally upregulated IDO to maintain low tissue concentrations of tryptophan, thus inhibiting the activity and proliferation of maternal T cells that would normally detect and destroy the allogeneic foetus. By inhibiting IDO, therefore, this tryptophan depletion could not be induced and T cell attack proceeded successfully to destroy the foetus.
This pioneering work diversified rapidly into investigating the links between raised levels of IDO and immunotolerance in both transplantion and cancer [76] ( Figure 4) . In addition to stimulating TGF- production, 3-HAA acts directly upon Th1 cells to suppress their pro-inflammatory activity, but has no discernible action on Th2 cells [78] [79] [80] although IDO activation overall may promote Th2 function [81] .
These two T cell populations normally exist in a delicate balance, with Th1 cells generating IFN helping to sustain macrophage activation and release the powerfully pro-inflammatory TNF- as well as other deleterious substances including ROS. The combination of these Th1-induced factors is anti-microbial but also tends to attack allogeneic cells, producing rejection of tissue allografts and foetal resorption or abortion. Th2 cells generate IL-4 which acts as a brake on the activation of macrophages by IFN, thus imposing an anti-inflammatory restraint on the system and contributing to graft retention and foetal protection [82, 83] . The preferential inhibition of Th1 cells, therefore, confers on 3-HAA an overall immunoprotective influence [82] .
In fact, IDO activation may not be the only trigger for this cascade. IFN- and other pro-inflammatory cytokines also induce kynurenine-2,3-dioxygenase (KMO) and kynureninase so that, as long as kynurenine is available, the levels of 3-HK, 3HAA and quinolinic acid generated by DCs will be sufficient to regulate the activity of immune system cells [84] . The resulting state of immune tolerance (tolerogenesis) seems to be produced by the kynurenine metabolites rather than by tryptophan depletion.
Although IDO is widely distributed in many tissues, the closely related enzyme tryptophan-2,3-dioxygenase (TDO) is largely confined to the liver. It also converts tryptophan to kynurenine and its subsequent metabolites and will therefore reduce T cell activity and immune surveillance, thus increasing the possibility of tumour formation as discussed above for IDO. In contrast to IDO, the activity of TDO is induced by glucocorticoids [85, 86] . and, because the secretion of these steroids occurs in response to stress, this link may contribute to the greater incidence of cancer resulting from chronic stress, for which TDO inhibitors might present a potential treatment [87, 88] .
Kynurenine metabolites help to regulate secretion of the tolerogenic Human Lymphocyte Antigen-G (HLA-G) [89] . In patients with HD, blood levels of this antigen correlate significantly with the levels of kynurenine metabolites in the blood. There is also a strong correlation between tryptophan metabolism and the size of the abnormally extended huntingtin protein which is believed to cause the disorder [27] , supporting the increasing evidence for a significant pathological role for kynurenines in Huntington's disease [22] .
Kynurenines and drug development
The discovery that kynurenine-derived metabolites of tryptophan could modulate the level of glutamate receptor activation focussed early interest on their potential roles in neurodegenerative disorders in which over-or underactivity of those receptors could produce excitotoxicity and neurodegeneration, or a general suppression of excitatory neurotransmission respectively. As this review indicates, some of those original thoughts may still be highly relevant in disorders such as AD and HD, where compounds that inhibit KMO in particular could slow the rate of neuronal loss. In schizophrenia, the contrary situation is encountered, with raised kynurenic acid levels that could be normalised by development of selective inhibitors of KAT II [21] . The pro-cognitive actions of KAT inhibition have been adequately confirmed by the finding that deletion of KAT II results in a similar degree of cognitive enhancement and memory function [40] . The potential value of the kynurenine pathway for the development of new drugs acting in disorders such as these, in which a degree of neuronal damage is involved, has been discussed previously [90] In addition, the identification of a range of molecular targets such as GPR35, Finally, the parallel work that has developed since the early 1980s of the actions of kynurenines in the CNS and their effects in the immune system seem to be moving closer towards an integrated view of their interaction. That may in turn result in the development of compounds that can regulate changes in the processes of CNS neurotransmission directly, but which can also modify the development and progression of inflammatory reactions that increasingly seem to underlie chronic CNS disorders such as AD and HD, but may also be relevant to conditions such as multiple sclerosis (MS) [91] and infection-induced dementias [92] . This is certainly a pathway that is likely to become more intriguing in the future.
Concluding remarks
Although the links between tryptophan metabolism to kynurenines and to 5-HT should not be forgotten, future research might benefit greatly from an increasing attention on the oxidative metabolism of tryptophan along the kynurenine pathway. The potential sites for interference may be under-or overactivated by their ligands, mutated genetically or modified epigenetically and should be regarded as druggable targets for pharmacological development with therapeutic value in a range of disorders in the nervous and immune systems. A summary of the main compounds which constitute the kynurenine pathway for the oxidative metabolism of tryptophan. The pathway is usually referred to in this way after the initial stable product of tryptophan oxidation, kynurenine, which was originally isolated from canine urine in the nineteenth century and named to reflect this.
Figure 2
The major cellular and molecular targets of kynurenic acid. The blockade of NMDA receptors was the first specific site of action to be identified [2] , followed A summary of the main compounds which constitute the kynurenine pathway for the oxidative metabolism of tryptophan. The pathway is usually referred to in this way after the initial stable product of tryptophan oxidation, kynurenine, which was originally isolated from canine urine in the nineteenth century and named to reflect this. 
